Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus Toripalimab in EGFR+ ESCC
NCT04880811Phase 2Unknown
- Sponsor
- Peking University
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Primary endpoint: Objective Response Rate up to 100 months. Status: unknown.
02
Drugs
afatinibtoripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04880811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880811.